E
RXi Pharmaceuticals (RXII) announced today that is has obtained an exclusive global licensing deal for a phase 2 ready product known as Samcyprone. RXi is licensing the drug from Hapten Pharmaceuticals, LLC. Under the terms of the Agreement RXi will obtain patent rights and assets. In exchange for RXi obtaining Samcyprone the company will be…